Unique ID issued by UMIN | UMIN000035382 |
---|---|
Receipt number | R000040313 |
Scientific Title | Compare the efficacy of diagnostic treatment with P-CAB and PPI before to do endoscopy for GERD patients. |
Date of disclosure of the study information | 2019/03/01 |
Last modified on | 2018/12/27 16:32:57 |
Compare the efficacy of diagnostic treatment with P-CAB and PPI before to do endoscopy for GERD patients.
Compare the efficacy of treatment with P-CAB and PPI in patients with GERD.
Compare the efficacy of diagnostic treatment with P-CAB and PPI before to do endoscopy for GERD patients.
Compare the efficacy of treatment with P-CAB and PPI in patients with GERD.
Japan |
Gastroesophageal reflux disease
Gastroenterology |
Others
NO
To compare the efficacy of Vonoprazan(20mg/day) vs Esomeprazole(20mg/day) for 1week treatment in patients with GERD by assessing the time(days) to be GERD symptom relief before to do endoscopy.
Efficacy
Time(days) to GERD symptom relief.
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Active
2
Treatment
Medicine |
Vonoprazan(Takecab)20mg once a day in the mornimg.
Esomeprazole(Nexium)20mg once a day in the mornimg.
20 | years-old | <= |
Not applicable |
Male and Female
1.Patients whose chief complain are heartburn or acetic acid more than 2days in a week.
2.Patients who are at least 20 years of age.
3.Patients whose main organs work.
4.Patients who have given written consent to participate in the study.
1.Patients with a history of hypersensitivity to components of Vonoprazan and Esomeprazole.
2.Patients taking PPI including Vonoprazan and Esomeprazole.
3.Patients taking Atazanavir sulfate and Rilpivirine hydrochloride.
4.Patients who are diagnosed Zollinger-Ellison syndrome and Pernicious anemia.
5.Patients who have complicated other severe diseases and whose clinical trials can not be safety performed or whose effect judgment is difficult.
6.Patients with malignant tumor complications.
7.Patients with a history of surgery of the upper gastrointestinal tract including the stomach and esophagus.
8.Patients who may be pregnant or pregnant.
9.Patients who judged by physician inappropriate to participate in clinical trials.
100
1st name | |
Middle name | |
Last name | Akihiro Tamaki |
Kitasato University
Internal gastroenterology
1-15-1 Kitasato Minami,Sagamihara,Kanagawa,Japan
042-778-8111
a.tamaki@kitasato-u.ac.jp
1st name | |
Middle name | |
Last name | Kengi Ishido |
Kitasato University
Internal gastroenterology
1-15-1 Kitasato Minami,Sagamihara,Kanagawa,Japan
042-778-8111
k.ishido@kitasato-u.ac.jp
Kitasato University
None
Self funding
NO
2019 | Year | 03 | Month | 01 | Day |
Unpublished
Preinitiation
2018 | Year | 09 | Month | 20 | Day |
2019 | Year | 03 | Month | 01 | Day |
2018 | Year | 12 | Month | 27 | Day |
2018 | Year | 12 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040313
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |